19 February 2025
19 February 2025
An NIH-funded clinical trial is underway investigating GLP-1RAs as a treatment for opioid use disorder.
The FDA has accepted Gilead’s new drug application with a decision expected by 19 June 2025.
Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.
Stoke will obtain a $165m upfront payment from Biogen upon completion of the transaction.
The approval is based on the outcomes from the open-label trials LITESPARK-004 and LITESPARK-005.
Jean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
